Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK announces NEJM publication of phase III study investigating mepolizumab in patients with EGPA
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GSK plc (LSE/NYSE:GSK) announced preliminary results of two pivotal phase III studies evaluating the efficacy and safety of mepolizumab
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Endpoint: patients initiated with Relvar Ellipta had twice the odds of achieving improvement in asthma control than patients in usual care.
GSK delivers another quarter of continued progress
GSK Q1 sales of £7.4 billion, +19% AER, + 5% CER Total EPS of 21.4p >100% AER, >100% CER; Adjusted EPS of 25.0p, +31% AER, +9% CER
Togo becomes first country in Africa to validate the elimination of lymphatic filariasis as a public health problem
LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted to humans through the bites of mosquitoes.
GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Follows regulatory submissions in US, EU and Canada
GSK makes change to financial reporting framework
GSK keeps its financial reporting framework under regular review to ensure that it remains current.
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK announces new scholarships to recognise retiring CEO Sir Andrew Witty’s contribution to global health
GSK today announced a new partnership with the London School of Hygiene & Tropical Medicine
UK Biobank, GSK and Regeneron announce largest gene sequencing initiative on world’s most detailed health database to improve drug discovery and disease diagnosis
Groundbreaking UK/US initiative will deliver first data within a year
GSK’s MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
MUSCA study shows asthma patients achieved improvements in their health-related quality of life and lung function with Nucala® (mepolizumab)
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
GSK announced the closure of agreement with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
Positive headline results from a non-inferiority lung function study.
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference
Results announcement for the fourth quarter 2016
View full Q4 2016 Results (PDF)
Luke Miels appointed President, Global Pharmaceuticals, GSK
Luke Miels has been appointed President, Global Pharmaceuticals, GSK.
Abbas Hussain to leave GSK
Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company.
GSK confirms closure of agreement to divest non-core assets to Aspen
GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN)
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
First injectable to be studied for efficacy in pre-exposure prophylaxis
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
The start of a phase III study investigating the effects of once-daily closed triple combination therapy (FF/UMEC/VI).